BlogTalkRadio uses cookies. By using our services, you're agreeing to our Cookies Policy. Got it

Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Myeloma Crowd Radio: Maria Chaudhry, MD, Ohio State University

  • Broadcast in Health
Myeloma Crowd Radio

Myeloma Crowd Radio


Follow This Show

If you liked this show, you should follow Myeloma Crowd Radio.

At last year's ASH meeting, there was excitement around a new antibody drug conjugate targeting a protein called BCMA from Glaxo Smith Klein. Results from their Phase I study showed that patients who had relapsed immunomodulators (like Revlimid), proteasome inhibitors (like Velcade) and even monoclonal antibodies (like daratumumab), responded when taking this drug alone (60% response rate).

Learn more from Dr. Maria Chaudhry of Ohio State University about current studies using this new drug and when patients could consider it in the course of their treatment. 

Thanks to our episode sponsor, Celgene.